Calculated bioavailable testosterone levels and depression in middle-aged men

McIntyre, Roger S.; Mancini, Deborah; Eisfeld, Beata S.; Soczynska, Joanna K.; Grupp, Larry A.; Konarski, Jakub Z.; Kennedy, Sidney H.

doi:10.1016/j.psyneuen.2006.06.005

Cited by 102 publications

(69 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In particular, testosterone has mood-enhancing properties and anti-depressant effects in men (Kanayama et al, 2007). Increased incidence of hypogonadism occurred in men with major anxiety and depressive disorder, and testosterone replacement effectively improves mood (McIntyre et al, 2006;Frye et al, 2008). In rodents, testosterone has anti-depressive-like effects in aged male mice and protective effects against the development of depressive-like behaviors in rats .…”

Section: Discussionmentioning

confidence: 99%

Perinatal exposure to di-(2-ethylhexyl) phthalate affects anxiety- and depression-like behaviors in mice

Yang

Wang

et al. 2015

Chemosphere

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Perinatal exposure to di-(2-ethylhexyl) phthalate affects anxiety- and depression-like behaviors in mice

Yang

Wang

et al. 2015

Chemosphere

View full text Add to dashboard Cite

“…This could explain our finding of increased SERT availability in the diencephalon in females. In depressed men, the sex steroid testosterone is decreased [35], with 34-61% biochemical hypogonadism in depressed males compared with 6-14% in healthy individuals [36]. This lack of testosterone in MDD may reduce SERT availability as a result of reduced conversion to oestrogen.…”

Section: Methodological Explanations For Inconsistent Findingsmentioning

confidence: 99%

Serotonin transporter binding with [123I]β-CIT SPECT in major depressive disorder versus controls: effect of season and gender

Ruhé

Booij

Reitsma

et al. 2009

Eur J Nucl Med Mol Imaging

View full text Add to dashboard Cite

Purpose The serotonin system is undoubtedly involved in the pathogenesis of major depressive disorder (MDD). More specifically the serotonin transporter (SERT) serves as a major target for antidepressant drugs. There are conflicting results about SERT availability in depressed patients versus healthy controls. We aimed to measure SERT availability and study the effects of age, gender and season of scanning in MDD patients in comparison to healthy controls. Methods We included 49 depressed outpatients (mean±SD 42.3±8.3 years) with a Hamilton depression rating scale score above 18, who were drug-naive or drug-free for ≥4 weeks, and 49 healthy controls matched for age (±2 years) and sex. Subjects were scanned with single photon emission computed tomography (SPECT) using [ 123 I]β-CIT. SERT availability was expressed as specific to nonspecific binding ratios (BP ND ) in the midbrain and diencephalon with cerebellar binding as a reference. Results In crude comparisons between patients and controls, we found no significant differences in midbrain or diencephalon SERT availability. In subgroup analyses, depressed males had numerically lower midbrain SERT availability than controls, whereas among women SERT availability was not different (significant diagnosis×gender interaction; p=0.048). In the diencephalon we found a comparable diagnosis×gender interaction (p=0.002) and an additional smoking×gender (p=0.036) interaction. In the midbrain the season of scanning showed a significant main effect (p=0.018) with higher SERT availability in winter. Conclusion Differences in SERT availability in the midbrain and diencephalon in MDD patients compared with healthy subjects are affected by gender. The season of scanning is a covariate in the midbrain. The diagnosis×gender and gender×smoking interactions in SERT availability should be considered in future studies of the pathogenesis of MDD.

show abstract

“…However, the connection between testosterone levels and depression vulnerability is not readily apparent, as both low and high testosterone levels have been associated with depressive symptoms, along with equivocal efficacy reported in studies investigating testosterone as a standalone treatment or adjunct therapy in depressed individuals (1). Despite this, the incidence of depression in men increases with age, coinciding with a decline in testosterone levels (2,3,4), and testosterone replacement has some efficacy in improving depressive symptoms in this population, as well as in men with refractory depression as an adjunct treatment to antidepressant medication (5,6,7,8). Moreover, hypogonadism in young males can precipitate depressive symptomology, supporting a protective role of testosterone against the development of affective disorders.…”

Section: Introductionmentioning

confidence: 99%

The Anxiolytic and Antidepressant-like Effects of Testosterone and Estrogen in Gonadectomized Male Rats

Carrier¹,

Saland²,

Duclot³

et al. 2015

Biological Psychiatry

101

View full text Add to dashboard Cite

Background While the influence of testosterone levels on vulnerability to affective disorders is not straightforward, research suggests this hormone may confer some degree of resiliency in men. We recently demonstrated a role for the dentate gyrus in mediating testosterone’s protective effects on depressive-like behavior in gonadectomized male rats. Here, testosterone may exert its effects through androgen receptor-mediated mechanisms or via local aromatization to estradiol. Methods Gonadectomized male rats were implanted with a placebo, testosterone, or estradiol pellet, and subsequent protective anxiolytic- and antidepressant-like effects of testosterone and its aromatized metabolite, estradiol, were then investigated in the open field and sucrose preference tests, respectively. Moreover, their influence on gene expression in the hippocampus was analyzed by genome-wide cDNA microarray analysis. Finally, the contribution of testosterone’s aromatization within the dentate gyrus was assessed by local infusion of the aromatase inhibitor, fadrozole, whose efficacy was confirmed by LC-MS/MS. Results Both hormones had antidepressant-like effects associated with a substantial overlap in transcriptional regulation, particularly in synaptic plasticity- and mitogen-activated protein kinase pathway-related genes. Further, chronic aromatase inhibition within the dentate gyrus blocked the protective effects of testosterone. Conclusions Both testosterone and estradiol exhibit anxiolytic- and antidepressant-like effects in gonadectomized male rats, while similarly regulating critical mediators of these behaviors, suggesting common underlying mechanisms. Accordingly, we demonstrated that testosterone’s protective effects are mediated, in part, by its aromatization in the dentate gyrus. These findings thus provide further insight into a role for estradiol in mediating the protective anxiolytic- and antidepressant-like effects of testosterone.

show abstract

Calculated bioavailable testosterone levels and depression in middle-aged men

Cited by 102 publications

References 25 publications

Perinatal exposure to di-(2-ethylhexyl) phthalate affects anxiety- and depression-like behaviors in mice

Perinatal exposure to di-(2-ethylhexyl) phthalate affects anxiety- and depression-like behaviors in mice

Serotonin transporter binding with [123I]β-CIT SPECT in major depressive disorder versus controls: effect of season and gender

The Anxiolytic and Antidepressant-like Effects of Testosterone and Estrogen in Gonadectomized Male Rats

Contact Info

Product

Resources

About